Preferred Provider Use Among Bioanalytical Lab Outsourcers
In Q3, 2019, ISR asked outsourcers of bioanalytical lab services about their organization’s use of preferred providers. The data show use of preferred providers is common practice when outsourcing bioanalytical lab work, 88% currently use a preferred lab for preclinical services and 90% currently use a preferred lab for clinical services. On average, respondents indicate that their company currently has 2.3 preferred labs for preclinical services and 2.6 preferred labs for clinical lab work. For more information, follow the link to the Bioanalytical Labs Market Dynamics and Service Provider Performance report preview.
Improving Clinical Logistics Outsourcing Relationships
In Q3, 2019, ISR asked 100 outsourcers of clinical logistics about several different scenarios that could potentially improve outsourcing relationships. Two scenarios were considered Very Likely – Likely to improve relationships by three-quarters of respondents: Improved technology integration and improvements to project management from both the sponsor and service provider.
Top 5 Selection Attributes Gaining Importance For Outsourced Bioanalytical Lab Services
In Q3, 2019, ISR asked outsourcers of bioanalytical lab services about their thoughts on 22 selection qualities that have become more important in the past year when choosing a provider for bioanalytical lab services. Assay development expertise (46%), and Technical expertise/experts (44%) top the list of lab qualities that are increasing in importance.
Clinical Materials Distribution by Location
In Q3, 2019, ISR asked outsourcers of clinical logistics about the proportion of clinical materials distributed to the following locations: trial sites, depots, warehouses, and directly to patients. The data show the majority of clinical materials are currently sent to trial sites (53%) and that only 5% are sent directly to patients. However, over the next three years, respondents anticipate the proportion of clinical materials going directly to patients will double.
2018-2023 Edition Of The CRO Market Size Projections
Since ISR first put out our CRO Market Size projections, there have been several other reports produced, with surprisingly similar figures. Some of these have future growth rates for the CRO market as high as >10% and some have them as low as ~5%. We are somewhere in the middle. ISR is projecting a CAGR from 2018 to 2023 of 7.5%. Remember that a lot can (and will) change between now and 2023, but we believe the fundamentals are in place for a growing outsourced clinical development market.
Most Important Attributes For EDC Provider Selection: Development vs. Post-Marketing
ISR recently surveyed 148 respondents on their experience with electronic data capture (EDC) systems, which have become essential tools to appropriately capture, review, and present clinical trial data.
Top 5 Selection Attributes For Outsourced eTMF Services
In a recent survey, ISR asked outsourcers of eTMF services about their thoughts on 22 selection qualities that drive eTMF provider selection. Overall ease of use tops the list as the most important driver for selection (25%), followed by Integration with other systems (17%), Data security (12%), Auditability (10%), and Systems performance/uptime (5%).
The Impact Of mHealth Technologies On Clinical Trial Spending
In Q3, 2018 ISR asked 48 users of mHealth technologies whether they anticipate changes in their companies’ clinical trials expenditure due to incorporating mHealth technologies into clinical trials. The data show that more than four-out-of-five respondents believe there will be an increase in spending in the coming 12 months.
Preferred Provider Use For IRT Services
In Q2, 2020, ISR asked 109 outsourcers of IRT services about their company’s use of preferred providers. Among respondents that are knowledgeable about their company’s preferred provider use, 44% currently have preferred provider agreements in place for IRT services. Among respondents with preferred providers for IRT services, their companies have an average of 2.7 preferred providers. On average, respondents reported that preferred providers complete 86% of all IRT work.
Technology In Clinical Trials: Differences By Company Size
When looking at industrywide trends, it’s helpful to remember that large sponsors have more resources to help them pursue new technology initiatives. With that in mind, explore where large vs. nonlarge sponsors differ in terms of openness to emerging trends in clinical development.